Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN R SCAGNELLI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1437268265
CMS profile
1144624
Location
RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$52,058.88

300 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 5 of 6; records 201–250 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN R SCAGNELLI

NPI 1437268265 · CMS profile ID 1144624

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 6; records 201–250 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437268265?year=2023&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN R SCAGNELLI, NPI 1437268265, CMS profile ID 1144624. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437268265?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOHN R SCAGNELLI, NPI 1437268265, CMS profile ID 1144624. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437268265?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOHN R SCAGNELLI, NPI 1437268265, CMS profile ID 1144624, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1437268265?year=2023&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

300 matching records · $52,058.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 300 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 300.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $17.0705/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998842985 CMS
Horizon Therapeutics plc $20.6705/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987070801 CMS
EMD Serono, Inc. $24.4005/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032524703 CMS
SK Life Science, Inc. $26.2805/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054783921 CMS
Celgene Corporation $5.7805/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015438301 CMS
GENZYME CORPORATION $1,460.0005/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050110663 CMS
Genentech USA, Inc. $16.6005/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040405879 CMS
Novartis Pharmaceuticals Corporation $24.8305/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993257417 CMS
GE HealthCare $13.9805/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039521423 CMS
TG Therapeutics, Inc. $22.6204/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051480865 CMS
Amgen Inc. $14.4104/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019971481 CMS
Horizon Therapeutics plc $23.4004/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987070799 CMS
ARGENX US, INC. $28.5304/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060438177 CMS
CSL Behring $6.9504/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042957329 CMS
PFIZER INC. $8.5204/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050384693 CMS
PFIZER INC. $0.6204/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050405625 CMS
Biogen, Inc. $19.8204/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012235531 CMS
GENZYME CORPORATION $38.1204/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050110559 CMS
GENZYME CORPORATION $12.0504/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050110561 CMS
GENZYME CORPORATION $17.7604/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050110617 CMS
Novartis Pharmaceuticals Corporation $3.6204/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993257415 CMS
EMD Serono, Inc. $13.8004/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032391255 CMS
Biogen, Inc. $32.2104/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012166265 CMS
CSL Behring $26.0204/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042957305 CMS
EMD Serono, Inc. $6.1904/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032498263 CMS
PFIZER INC. $22.3204/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050676207 CMS
Mallinckrodt Hospital Products Inc. $21.9204/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042887753 CMS
Alexion Pharmaceuticals, Inc. $18.1004/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017009107 CMS
Biogen, Inc. $125.0004/04/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012131271 CMS
ANI Pharmaceuticals, Inc. $62.5603/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034179921 CMS
Genentech USA, Inc. $4.6303/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040405973 CMS
Celgene Corporation $17.3603/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015438265 CMS
Novartis Pharmaceuticals Corporation $22.9303/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993257399 CMS
AbbVie Inc. $19.7103/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998842981 CMS
Lilly USA, LLC $13.3203/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031714697 CMS
TG Therapeutics, Inc. $400.0003/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051480959 CMS
Avion Pharmaceuticals $14.9003/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032973555 CMS
TG Therapeutics, Inc. $23.6803/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051480943 CMS
Axsome Therapeutics, Inc. $22.8603/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056166623 CMS
TG Therapeutics, Inc. $23.8803/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051480821 CMS
AbbVie Inc. $5.4103/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998842973 CMS
AbbVie Inc. $20.6003/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998842977 CMS
GENZYME CORPORATION $38.4603/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050110531 CMS
Axsome Therapeutics, Inc. $26.6803/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056166625 CMS
GENZYME CORPORATION $35.7103/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050110547 CMS
Biogen, Inc. $24.8503/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012169227 CMS
TG Therapeutics, Inc. $5.7803/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051480955 CMS
CSL Behring $21.4603/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042957269 CMS
Genentech USA, Inc. $16.8703/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040405865 CMS
Genentech USA, Inc. $1.0303/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040405871 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $118,429.57 412
PY2020 $38,803.27 93
PY2021 $58,425.08 131
PY2022 $47,926.89 237
PY2023 $52,058.88 300
PY2024 $57,406.42 310
PY2025 $56,364.51 384

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,477,506.69 75
PY2024 Principal investigator $1,628,765.17 52
PY2023 Principal investigator $1,530,243.64 74
PY2022 Principal investigator $1,263,839.43 68
PY2021 Principal investigator $893,217.46 74
PY2020 Principal investigator $963,358.74 52
PY2019 Principal investigator $1,152,764.37 32

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

75 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $800.00 12/12/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200221
Principal investigator 1 TG Therapeutics, Inc. $14,003.60 12/09/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200297
Principal investigator 1 GENZYME CORPORATION $19,077.00 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226130765
Principal investigator 1 TG Therapeutics, Inc. $400.00 11/30/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200241
Principal investigator 1 TG Therapeutics, Inc. $1,601.16 11/25/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200293
Principal investigator 1 GENZYME CORPORATION $16,984.80 11/17/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130749
Principal investigator 1 GENZYME CORPORATION $13,191.30 11/17/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130756
Principal investigator 1 TG Therapeutics, Inc. $3,900.00 11/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200305
Principal investigator 1 TG Therapeutics, Inc. $600.00 11/04/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200301
Principal investigator 1 TG Therapeutics, Inc. $250.00 11/04/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200303
Principal investigator 1 TG Therapeutics, Inc. $21,494.20 11/01/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200295
Principal investigator 1 Genentech, Inc. $15,973.00 10/28/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211624621
Principal investigator 1 Genentech, Inc. $4,916.00 10/28/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211624628
Principal investigator 1 TG Therapeutics, Inc. $250.00 10/24/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200299
Principal investigator 1 Genentech, Inc. $10,298.00 10/15/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211624625
Principal investigator 1 ARGENX US, INC. $5,469.00 10/10/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237161252
Principal investigator 1 ARGENX US, INC. $11,573.00 10/10/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237161257
Principal investigator 1 ARGENX US, INC. $400.00 10/08/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237161262
Principal investigator 1 ARGENX US, INC. $775.00 10/08/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237161268
Principal investigator 1 TG Therapeutics, Inc. $30,534.40 09/30/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200281
Principal investigator 1 TG Therapeutics, Inc. $4,540.00 09/30/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200287
Principal investigator 1 GENZYME CORPORATION $66,390.75 09/29/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130681
Principal investigator 1 GENZYME CORPORATION $500.00 09/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226130656
Principal investigator 1 TG Therapeutics, Inc. $35,111.40 08/31/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200279
Principal investigator 1 ARGENX US, INC. $59.34 08/27/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237161248
Principal investigator 1 Genentech, Inc. $530.00 08/26/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211624616
Principal investigator 1 GENZYME CORPORATION $2,155.00 08/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130642
Principal investigator 1 TG Therapeutics, Inc. $2,350.00 08/21/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200285
Principal investigator 1 GENZYME CORPORATION $13,277.10 08/04/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130583
Principal investigator 1 GENZYME CORPORATION $8,665.70 08/04/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130586
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 08/04/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200291
Principal investigator 1 TG Therapeutics, Inc. $14,426.00 07/31/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200277
Principal investigator 1 TG Therapeutics, Inc. $6,404.64 07/29/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200289
Principal investigator 1 GENZYME CORPORATION $21,628.00 07/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226130589
Principal investigator 1 TG Therapeutics, Inc. $750.00 07/22/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200283
Principal investigator 1 Genentech, Inc. $15,692.00 07/21/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211624612
Principal investigator 1 GENZYME CORPORATION $15,850.60 07/02/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130551
Principal investigator 1 Genentech, Inc. $660.00 06/18/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211624586
Principal investigator 1 TG Therapeutics, Inc. $1,000.00 06/09/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200267
Principal investigator 1 TG Therapeutics, Inc. $2,050.00 06/05/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200265
Principal investigator 1 TG Therapeutics, Inc. $21,322.30 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200263
Principal investigator 1 GENZYME CORPORATION $14,570.25 05/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130448
Principal investigator 1 GENZYME CORPORATION $20,802.00 05/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226130467
Principal investigator 1 Genentech, Inc. $21,388.00 05/09/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211624608
Principal investigator 1 ARGENX US, INC. $18,238.00 05/02/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237161245
Principal investigator 1 TG Therapeutics, Inc. $4,269.76 04/24/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200271
Principal investigator 1 TG Therapeutics, Inc. $3,700.00 04/23/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200261
Principal investigator 1 GENZYME CORPORATION $31,740.00 04/14/2025 Non-covered Recipient Entity
Velocity Clinical Research, Savannah
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148810
Principal investigator 1 GENZYME CORPORATION $13,277.10 04/02/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130317
Principal investigator 1 TG Therapeutics, Inc. $26,350.00 03/31/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200253
Principal investigator 1 Genentech, Inc. $675.00 03/26/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211624605
Principal investigator 1 GENZYME CORPORATION $1,035.00 03/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130256
Principal investigator 1 GENZYME CORPORATION $15,754.35 03/17/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130251
Principal investigator 1 TG Therapeutics, Inc. $1,700.00 03/13/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200275
Principal investigator 1 TG Therapeutics, Inc. $5,337.20 03/10/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200269
Principal investigator 1 GENZYME CORPORATION $3,830.00 03/04/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130320
Principal investigator 1 TG Therapeutics, Inc. $4,000.00 02/28/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200251
Principal investigator 1 GENZYME CORPORATION $5,415.00 02/18/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130238
Principal investigator 1 GENZYME CORPORATION $7,601.73 02/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Savannah
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226148806
Principal investigator 1 Genentech, Inc. $2,746.00 02/18/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211624597
Principal investigator 1 Genentech, Inc. $65,298.00 02/14/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211624601
Principal investigator 1 TG Therapeutics, Inc. $500.00 02/11/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200259
Principal investigator 1 TG Therapeutics, Inc. $1,000.00 01/31/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200249
Principal investigator 1 Genentech, Inc. $380.00 01/28/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211624592
Principal investigator 1 TG Therapeutics, Inc. $3,500.00 01/28/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200257
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,078.00 01/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190310580
Principal investigator 1 GENZYME CORPORATION $19,544.80 01/13/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226130308
Principal investigator 1 GENZYME CORPORATION $5,769.00 01/13/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226130310
Principal investigator 1 GENZYME CORPORATION $22,518.00 01/13/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226130314
Principal investigator 1 GENZYME CORPORATION $7,842.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226130328
Principal investigator 1 GENZYME CORPORATION $7,465.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226130332
Principal investigator 1 TG Therapeutics, Inc. $1,900.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226200255
Principal investigator 1 TG Therapeutics, Inc. $3,850.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200273
Principal investigator 1 Novartis Pharmaceuticals Corporation $274,669.12 01/02/2025 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190312271
Principal investigator 1 Novartis Pharmaceuticals Corporation $420,174.05 01/01/2025 Non-covered Recipient Entity
RALEIGH NEUROLOGY ASSOCIATES
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190301311